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Abstract
Spinocerebellar ataxia (SCA) is a heterogeneous group of neurodegenerative ataxic disorders with autosomal dominant 
inheritance. We aim to provide an update on the recent clinical and scientific progresses in SCA where numerous novel genes 
have been identified with next-generation sequencing techniques. The main disease mechanisms of these SCAs include toxic 
RNA gain-of-function, mitochondrial dysfunction, channelopathies, autophagy and transcription dysregulation. Recent stud-
ies have also demonstrated the importance of DNA repair pathways in modifying SCA with CAG expansions. In addition, 
we summarise the latest technological advances in detecting known and novel repeat expansion in SCA. Finally, we discuss 
the roles of antisense oligonucleotides and RNA-based therapy as potential treatments.
Keywords Spinocerebellar ataxia · Molecular diagnosis · Next-generation sequencing
Introduction
The Spinocerebellar ataxias (SCA) are a subset of hereditary 
cerebellar ataxias that are autosomal dominantly transmitted. 
They are progressive neurodegenerative diseases that share 
the clinical features of ataxia, which arise from the pro-
gressive degeneration of the cerebellum but can also affect 
other connected regions, including the brain stem. They are a 
highly heterogenous group of disorders with a complex gen-
otype–phenotype spectrum; many SCAs are caused by CAG 
nucleotide repeat expansions that encode polyglutamine, and 
therefore, involve the toxic polyglutamine protein (polyQ) 
(Fig. 1) [1]. Recent advances in next-generation sequenc-
ing have identified new genes implicated in SCAs provid-
ing insights into disease transmission and pathogenesis. 
Here, we discuss updates in epidemiology, clinical features, 
molecular mechanisms and their potential implications in 
the future.
What is new in the epidemiology of SCA 
and its subtypes?
A recent systemic review shows that the global prevalence of 
SCA is 3 in 100,000 [2], however, a wide regional variation 
exists. SCA3 is commonest subtype around the globe [3–5], 
SCA2 is more prevalent in Cuba than SCA3 whilst SCA7 
is the most frequent subtype in Venezuela due to strong 
founder’s effect [6, 7]. SCA6 is one of the most common 
ADCA in the North of England, with a global prevalence 
of 5.2/100,000 [8]. There are various mutations described 
in SCA, although repeat expansions still account for almost 
half of SCA diagnosis in European cohort. In 412 undiag-
nosed autosomal dominant cerebellar ataxia (ADCA) with-
out known repeat expansion, 59 individuals (14.3%) were 
found to harbor pathogenic variants [9]. Thirty five of these 
variants (8.5%) belong to channel genes. In contrast, conven-
tional mutations in channel genes are rare in Han Chinese 
cohort [10]. In another cohort of 194 individuals with undi-
agnosed ADCA, SCA14 accounts for 6.7% of the studied 
population [11]. Other similar studies in Germany, United 
Kingdom, France, United States, Japan and Taiwan confirm 
the relative rarity of SCA 8, 23, 35, 36 and 42. They are each 
responsible for less than 1% of undiagnosed ADCA [12–18] 
although the advance in diversity genetics will further reveal 
the frequency of these genes in other populations.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0041 5-018-9076-4) contains 
supplementary material, which is available to authorized users.
 * Roisin Sullivan 
 r.sullivan@ucl.ac.uk
1 Department of Neuromuscular Diseases, UCL Queen’s 
Square Institute of Neurology, Queen’s Square House, 
Queen’s Square, London WC1N 3BG, UK
 Journal of Neurology
1 3
Make sense of SCA clinical features
The core triad of symptoms of SCAs include gait ataxia 
and incoordination, nystagmus/visual problems and dys-
arthria. Patients can present with additional features such 
as pyramidal, extrapyramidal signs, ophthalmoplegia and 
cognitive impairment in specific SCAs. Harding’s classi-
fication of ADCA in 1982 is still useful in the clinical set-
ting (Fig. 2) [19]. ADCA type 1 describes cerebellar ataxia 
with variable additional signs. This list is ever expanding 
and includes SCA1–4, 8, 10, 12–14, 15, 17–22, 25, 27, 
28, 31, 32, 34–37, 38, 42–44, 46, 47, ataxia with DNMT1 
and DRPLA [20–23]. ADCA type 2 describes cerebellar 
ataxia with pigmentary macular degeneration and con-
sists of only SCA 7 [20]. ADCA type 3 refers to ‘pure’ 
cerebellar ataxia, which includes SCA 5, 6, 11, 23, 26, 30, 
37, 41 and 45 [20, 24]. Several SCAs have characteristic 
clinical features in addition to cerebellar ataxia and helps 
distinguish them from other subtypes. For instance, SCA 
12, 15 and 27 have upper limb postural tremor [25–27]; 
SCA 14 may have myoclonus and task-specific dystonia 
[28]; and a subset of SCA 36 have facio-lingual fascicula-
tion with sensorineural hearing loss [29]. Table 1 shows 
a non-exhaustive list of distinctive clinical signs that fea-
ture prominently with cerebellar ataxia, adapted from a 
recent systematic review [30]. International Parkinson and 
Movement disorders Task Force recently proposes a new 
classification of SCA, dividing them into pure or relatively 
pure ataxia and complex ataxia, which overlaps with above 
mentioned ADCA classification [31]. A phenotype-first 
approach remains pertinent in molecular diagnosis of rare 
Fig. 1  Mechanism of poly-
glutamine protein expansion 
repeats. a Normal translation 
of polyglutamine repeat within 
normal repeat range, producing 
normal protein transcript and 
protein folding. b Pathogenic 
polyglutamine expansion repeat 
length leads to translation of 
expanded abnormal PolyQ 
repeat, which leads to protein 
misfolding. Misfolded polyQ 
proteins form aggregates which 
lead to various cellular process 
dysfunctions, leading to cell 
toxicity and degeneration. 
PolyQ polyglutamine proteins
Fig. 2  Harding’s classifica-
tion of Spinocerebellar Ataxia, 
detailing the classification of 
SCA based on symptom presen-
tation and the associated SCAs 
with that classification
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genetic disorders (Fig. 3) [32]. Clinicians should also con-
sider genetic testing for primary episodic ataxias (EA), 
especially with history of episodic attacks of imbalance, 
dysarthria, vertigo and/or diplopia lasting hours–days. 
EAs are autosomal dominant channelopathies and they 
mostly manifest before age 20 years [33]. They can be 
associated with other paroxysmal neurological disorders 
such as migraines, epilepsy and dystonia. Patients with 
EA type 1 also have interictal myokymia. However, pro-
gressive cerebellar ataxia may also occur in a proportion 
of patients with non-expansion mutations in KCNA1 and 
CACNA1A, especially later in the disease course [34, 35]. 
Unfortunately, the utility of clinical–genetic classification 
in SCA is limited by high level of phenotype–genotype 
overlap.
Advances in molecular diagnoses 
and disease mechanisms
Advances in next-generation sequencing (NGS) have facil-
itated further insights into the molecular causes of SCA. 
When NGS becomes translated to clinical practise, it has 
the potential to increase the success of molecular diagno-
sis for patients currently undiagnosed by standard genetic 
testing. Recent successes include conventional mutations 
in CCDC88C, TRPC3, CACNA1G, MME, GRM1, FAT2, 
PLD3 and PUM1 [23, 24, 36–40] since the last update in this 
journal in 2015 (see Table 2) [41]. Exome sequencing has 
an average diagnostic rate of 36% compared to target rese-
quencing panel of 17% [42]. Exome sequencing identifies 
less classical phenotype–genotype correlations and detects 
new mutations in known cerebellar genes [43]. We outline 
the roles of toxic RNA gain-of-function, mitochondrial 
Table 1  SCA subtypes with associated clinical signs that feature 
prominently with cerebellar ataxia
ATN1 atrophin 1, mutation responsible for dentatorubral–pallidoluy-
sian atrophy, DNA methyltransferase 1, mutation responsible for 
ADCA-deafness and narcolepsy
Associated clinical features Genetic subtypes
Peripheral neuropathy 1, 2, 3, 4, 18, 25, 38, 43, 46
Pyramidal signs 1, 3, 7, 8, 10, 14, 15, 17, 35, 40, 43
Dystonia 3, 14, 17, 20, 35
Myoclonus 14
Parkinsonism 2, 3, 10, 14, 17, 19/22, 21
Tremor 12, 15, 27
Chorea 17, 27, DRPLA
Cognitive impairment 2, 8, 13, 17, 19/22, 21, 36, 44, DRPLA
Psychiatric symptoms 2, 17
Ophthalmoplegia 2, 3, 28, 40
Visual impairment 7
Face/tongue fasciculation 36
Ichthyosiform plaques 34
Seizures 10, 19/22, ATN1
Narcolepsy DNMT1
Hearing loss 31, 36, DNMT1
Fig. 3  Flowchart of diagnosis 
pathway based on either posi-
tive or negative result of each 
diagnostic test. −ve—negative 
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defects, channelopathy, autophagy and transcriptional dys-
regulation in pathogenesis of SCA.
Toxic RNA gain‑of‑function
Non-coding repeat expansions are implicated in SCA sub-
types that include SCA 8, 10, 12, 31, 36 and 37. The hall-
marks are transcribed nuclear accumulations of repeat RNA-
binding proteins that can cause RNA toxicity and lead to 
disease pathogenesis (see Fig. 4) [44]. An intronic ATTCT 
pentanucleotide repeat expansion in ATXN10 has been 
found to cause SCA10, with pathogenicity in the range of 
800–4500 repeats [45]. Cytoplasmic and nuclear foci form 
in SCA10 cells and SCA10 transgenic mice brain from 
degradation-resistant, aggregated AUUCU RNA, which is 
formed from the splicing out of intron 9 from ATXN10 pre-
mRNA. The expanded AUUCU RNA binds to heterogene-
ous nuclear ribonucleoprotein K (hnRNPK), a spicing factor, 
causing its sequestration and loss of function. Ultimately this 
leads to the mitochondrial accumulation of protein kinase C 
δ (PKCδ) and apoptosis of SCA10 cells [46]. An intronic 
GGC CTG hexanucleotide repeat expansion was found in the 
gene NOP56 using genome-wide linkage, responsible for 
SCA 36. Patients’ lymphoblastoid cells contain RNA foci, 
and transcription of MIR1292, a neighbouring miMRA is 
reduced. These implicate a toxic RNA gain-of-function path-
ological mechanism in SCA 36 [29]. A toxic gain of function 
effect was found to be implicated in SCA8 pathogenesis, 
with the CTG CAG repeat expansion, which is bidirection-
ally expressed, causing [CUG]n transcript accumulation 
of ribonuclear inclusions that localise with the RNA bind-
ing protein Mbnl1. The downstream effects and alternative 
splicing contribute to the movement disorder phenotype in 
a SCA8 mice model [47]. Bidirectional expression of sense 
[CUG]n and antisense [CAG]n has been found in other dis-
orders such as at the DM1 locus [48] and in HDL2, which 
also forms ribonuclease inclusions [49]. Most recently an 
unstable intronic ATTTC repeat has been identified as the 
pathogenic cause of SCA37 in two Spanish cohorts, dys-
regulating reelin adaptor protein disabled-1 coding DAB1 
expression, leading to alternative splicing, an RNA switch 
and an upregulation of reelin-DAB1 signalling in the SCA37 
cerebellum [50].
Mitochondrial dysfunction
Recently advances have been made in the understanding of 
mitochondrial dysfunction and ataxia, with several genes 
related to mitochondrial function identified. These include 
mutations in OPA1, a mitochondrial dynamin-like GTPase 
and POLG [9], coding for the catalytic subunit of mitochon-
drial DNA polymerase gamma, as well as MTATP6 [22]; 
both of which involve mitochondrial dysfunction. Functional 
mitochondria are required for all cell processes including 
cell proliferation, differentiation, apoptotic cell death and 
are a crucial part of signalling cascades [51]. Findings have 
Table 2  Summary of major clinical characteristics of novel SCA genes described since 2015
CCDC88C coiled-coil domain containing 88C, JNK c-Jun N-terminal kinase, TRPC3 transient receptor potential cation channel subfamily C 
member 3, CACNA1G voltage sensor S4 segment of domain IV in Cav3.1T-type calcium channel protein MME neprilysin, GRM1 glutamate 
metabotropic receptor 1, FAT2 FAT atypical cadherin 2, PLD3 phospholipase D3, PUM1 RNA-binding protein Pumilio1
Gene/locus Mutation Number of pedigrees Clinical features Pathogenic mechanisms
CCDC88C (SCA 40) [36] Missense c.1391G>A 
(pR464H)
4 Probands from 1 family Cerebellar ataxia, hyper-
reflexia
JNK pathway hyperphos-
phorylation induced 
cellular apoptosis
TRPC3 (SCA 41) [37] Missense c.2285G>A 
(pR762H)
1 Proband from 1 family Cerebellar ataxia Toxic gain-of-function, 
channelopathy
CACNA1G (SCA 42) [38, 
57]
Missense c.5144G>A 
(pR1715H)
30 Probands from 5 
families
Cerebellar ataxia Haplo-insufficiency of 
T-type calcium channel
MME (SCA 43) [39] Missense c.428G>A 
(p.C143Y)
7 Probands from 1 family Cerebellar ataxia with 
peripheral neuropathy
Haplo-insufficiency of 
neprilysin, a zinc-depend-
ent metalloproteinase
GRM1 (SCA 44) [40] Missense c.2375A>G 
(p.Y792C)
c.785A>G (p.Y262C)
7 Probands from 2 families Cerebellar ataxia with 
pyramidal sign
Toxic gain-of-function 
metabotropic glutamate 
receptor 1
FAT2 (SCA 45) [24] Missense c.10946G>A 
(p.R3649Q)
c.10758G>C (p.K3586N)
6 Probands from 1 family Cerebellar ataxia ?affect cell adhesion
PLD3 (SCA 46) [24] Missense c.923T>C 
(L308P)
11 Probands from 1 family Cerebellar ataxia with 
peripheral neuropathy
Haplo-insufficiency of 
phospholipase D activity
PUM1 (SCA 47) [23] Missense g.31414862 T>A 
(p.T1035S)
9 Probands from 1 family Cerebellar ataxia Haplo-insufficiency of 
PUM1
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suggested that mitochondrial dysfunction and reactive oxy-
gen species (ROS) may be implicated in SCA2 pathogen-
esis, with an increase in mitochondrial oxidative stress in 
SCA2 patient fibroblasts, as well as changes in mitochon-
drial respiratory chain (MRC) enzymes and in mitochon-
drial morphology. Importantly these effects were increased 
in a SCA2 fibroblast line with an expanded CAG repeat 
from a patient yet to exhibit clinical symptoms, suggesting 
that mitochondrial dysfunction may precede disease onset. 
Furthermore, the antioxidant coenzyme Q10 (CoQ10) was 
found to improve oxidative stress in fibroblasts [52]. Oxi-
dative damage is a frequent feature of neurodegenerative 
conditions, including Alzheimer’s disease and Parkinson’s 
disease, due to the brains high oxygen utilisation and high 
content of oxidisable polyunsaturated fatty acids [53]. The 
polymorphic locus A100398G has been implicated in early 
age of onset in Cuban SCA2 patients [54] and has recently 
been described in a more severe cognitive phenotype in a 
42 SCA2 cohort, corroborating with prior findings in the 
Cuban cohort [55].
Channelopathies
Mutations coding for ion channel subunits or regulatory 
proteins, channelopathies, are frequently involved in the 
pathology of SCAs. Inherited channelopathies can alter 
ion channel function by mechanisms including inhibiting 
the ion movement through an open channel pore and alter-
ing ion channel gating through changes to channel opening 
processes or inactivation processes [56]. A recent study 
using amplicon-based panel sequencing for 65 genes on 
412 index patients found that channelopathies (with muta-
tions in CACNA1A, CACNA1G, KCND3 and KCNC3 in 
particular) had the earliest age of onset, longest disease 
duration and slowest disease progression, as well as purest 
cerebellar presentation. Interestingly they found a promi-
nent implication of SPG7 and CACNA1A in ataxic point 
mutations [9].
In fact, several newly described SCA gene mutations 
(GRM1, CACNA1G, TRPC3) are implicated on physio-
logical functions of the cellular channels [37, 38, 40, 57]. 
Transient receptor potential C3 (TRPC3) mutation occurs 
in a highly conserved region of the nonselective cation 
channel and is proposed to affect regulation of channel 
gating [37]. It has only been described in a sporadic case 
of adult-onset cerebellar ataxia. Calcium voltage-gated 
channel subunit alpha 1 G (CACNA1G) mutation leads 
to altered physiological property in the low voltage-gated 
calcium channel and causes a relatively pure cerebellar 
ataxia [38, 57]. CACNA1G channels are most prominently 
expressed in Purkinje cells and deep cerebellar nuclei. 
Electrophysiological study demonstrates that the mutation 
shifts the current–voltage and the steady-state activation 
curves of the mutant transfected cells positively [57]. In 
silico this causes decreased neuronal excitability. Gluta-
mate metabotropic receptor 1 (GRM1) gain-of-function 
mutations result in excessive glutamate receptor signalling 
and intracellular calcium level [40]. The authors hypoth-
esised excitotoxicity in cerebellar Purkinje cells as the 
cause of ADCA in two families.
Fig. 4  Mechanism of RNA 
foci formation and effects. a 
Pathogenic SCA intronic and 
exonic expansion repeats; b 
transcription of expanded repeat 
into expanded mRNA/pre-RNA; 
c binding of regulatory binding 
proteins (RBP) to abnormal 
mRNA transcript; d RBP pro-
tein sequestration and abnormal 
transcript aggregation; e effects 
of RBP sequestration on cellular 
processes. RBP regulatory bind-
ing proteins, RAN repeat-associ-
ated non-ATG 
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Autophagy
Autophagy is one of the main pathways for degradation of 
misfolded proteins; the other is the ubiquitin–proteasome 
system. Autophagy has been linked to neurodegeneration 
[58]. Both of SCA 3 fibroblast and SCA 7 mouth model 
demonstrate impaired autophagy [59, 60]. A mammalian 
target of rapamycin (mTOR) inhibitor that upregulates 
autophagy clears ataxin-3 and aggregates in brain in a SCA 
3 mouse model. This appears to slow motor deterioration 
[61]. Until recently, it remains unclear whether the misfolded 
protein accumulation causes the dysfunction of autophagy 
or whether impaired autophagy leads to accumulation of 
misfolded protein. Ashkenazi et al. demonstrate that wide-
type ataxin-3 polyglutamine repeat interacts with beclin 1, a 
key initiator of autophagy [62]. This interaction permits the 
deubiquitinase activity of ataxin-3 to protect beclin 1 from 
proteasome-mediated degradation. Thus, it allows autophagy 
to occur. Long polyglutamine expansion in mutant ataxin-3 
competes with wide type ataxin-3 interaction with beclin 1 
and leads to impaired starvation-induced autophagy. This 
highlights the direct role abnormally repeat expansion plays 
in neurodegeneration of SCA other than protein aggregation.
Transcriptional dysregulation
The molecular mechanisms of number SCAs (SCA 1, 2, 3, 
7, 17) involve interference with transcription through differ-
ent mechanisms [63]. These include protein–DNA interac-
tions, acetylation, phosphorylation and RNA interference. 
The mutant protein Ataxin-1, involved in SCA1 pathogen-
esis, is a transcription activator, whilst the polyglutamine 
expansion of SCA 17 occurs within the TATA box-binding 
protein (TBP), an essential transcription factor [64, 65]. A 
recently described mutation in RNA-binding protein Pumilio 
(PUM1) results in ADCA, coined SCA 47 [23]. Experiments 
in patients’ fibroblasts demonstrated that PUM1 protein acts 
as atranscription repressor. Reduced expression of PUM1 
suppresses dendritic arborization. Interestingly, the phe-
notypic severity of PUM1 mutation varies with the degree 
which the missense mutations/deletion reduce PUM1 protein 
levels. Around 50% reduction of PUM1 protein leads to a 
severe syndromic development delay whilst 25% reduction 
produces adult-onset cerebellar ataxia.
Genetic modifiers
The clinical diversity of the hereditary cerebellar ataxias 
in terms of age of onset, progression and severity of dis-
ease, strongly suggests the presence of modifying factors. 
We are beginning to dissect the complex mechanisms of 
genetic modifiers through the delineation of molecular 
pathways in the era of high-throughput sequencing. Com-
mon genetic variants, with a significant effect size, may act 
as genetic modifiers in rare mendelian conditions such as 
SCAs. A Genome-Wide Association Studies (GWAS) on 
Huntington Disease (HD), a (CAG)n expansion disorder, 
identified three significant loci with enrichment in DNA 
repair networks [66]. Subsequently, genotyping of these 
single nucleotide polymorphisms (SNPs) in 1462 subjects 
with CAG repeat SCAs and HD showed a significant asso-
ciation between DNA repair genes and the age at onset of 
SCAs and HD, with SNPs in FAN1 and PMS2 reaching 
the lowest p values [67]. FAN1 is a repair nuclease that is 
recruited to sites of crosslink damage and PMS2 endonucle-
ase is a mismatch repair (MMR) protein [68, 69]. In another 
association study of 137 parent–child transmissions in SCA 
3, a variant ERCC6 (Cockayne syndrome protein CSB) is 
associated with an expansion bias of (CAG)n [70]. Tight 
DNA repair regulation is an integral process to maintain 
integrity of expansions in replication and translation [71]. 
Dysregulation of DNA repair genes is postulated to result 
in somatic expansions in non-expanding cells of SCAs with 
trinucleotide repeat expansions and subsequent disease pro-
gression. An International GWAS of repeat expansion ataxia 
will be extremely valuable to provide further insights into 
the genetic factors influencing the clinical characteristics of 
these disorders.
Advances in diagnosis of repeat expansion 
disorders
The vast heterogeneity of SCA highlights the effectiveness 
of whole-exome and -genome sequencing (WES/WGS) as a 
diagnostic tool. Multiple reads are required for SCAs with 
conventional disease-causing mutations including single-
nucleotide polymorphisms (SNPs), deletions and insertions, 
to span the full length of the nonreference allele [72]. Cur-
rently, high-throughput sequencing technologies are limited 
to read lengths of approximately 150 base pairs (bp), how-
ever, pathogenic expansion repeats can span to thousands 
of bp in size, therefore, being unidentifiable by short-read 
sequencing technologies.
Repeat primed-PCR and subsequent fragment analy-
sis is widely used to detect repeat expansions, such as the 
repeat expansion in the C9orf72 locus implicated in both 
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal 
Dementia (FTD). However, these approaches have a frequent 
risk of misinterpretation due to false positives and negatives 
because of indels in the repeat flanking regions and vari-
ability in diagnostic laboratory protocols [73]. In addition, 
repeat length size cannot be estimated by these techniques. 
The current gold standard for estimating repeat length is 
Southern blotting which requires substantial amounts of 
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DNA (approximately 10 µg) and is vulnerable to somatic 
heterogeneity, reducing the precision of size estimation [74]. 
A novel method named tethering PCR, has recently been 
proposed by Cagnoli et al. to identify pathogenic expansions 
and estimate repeat size in SCA1, 2, 3, 6 and 7, as well as 
recognise large alleles and repeat interruptions, negating the 
need to perform a secondary test (i.e. Southern blot) [75].
Long-read sequencing technologies such as the Oxford 
Nanopore sequencing and PacBio single-molecule real-time 
(SMRT) facilitate the sequencing of more than 10,000 bp 
DNA sequence lengths. Nanopore sequencing uses a pro-
tein nanopore covalently attached to an adaptor molecule to 
identify unlabeled nucleoside 5′ monophosphate molecules. 
It has an average accuracy of 99.8%. It can function without 
exonuclease and has a high accuracy of not registering the 
same nucleotide twice due to translocation through the nano-
pore [76]. By contrast, SMRT sequencing uses real-time 
imaging of fluorescently tagged nucleotides during DNA 
synthesis along template models, using DNA polymerase as 
a reaction driver [77]. PacBio reads have around a 15% aver-
age higher error rate [78], however, Oxford Nanopore plat-
forms also have limitations with their MiniION sequencer 
having a reported estimated base-calling error rate of 38.2% 
[79].
Due to the popularity of WGS, developing a method for 
pathogenic repeat expansions has been of interest. Recently 
a software package called ExpansionHunter has been devel-
oped by Illumina that can determine the size of repeats of 
varying size, including very large pathogenic expansions 
much longer than the read length, using PCR-free WGS 
data [80]. They developed an algorithm able to identify 
reads in several different conditions; reads that span the 
full length, reads that fully contain the repeat [‘in-repeat’ 
reads (IRR)] and repeats that include the repeat and flanking 
sequence on one side of the repeat. The software correctly 
classified all C9orf72 expanded samples in an ALS cohort 
as either expanded, possibly expanded or wild-type as well 
as 8 other pathogenic repeat expansions, including sam-
ples from SCA1 and SCA3 cohorts. The tool facilitates the 
screening of repeat expansions using a single run of WGS, 
with PCR-free WGS data. Development is still in progress 
as currently the software requires an STR to be specified 
by reference coordinate and repeat motif. However, future 
association studies and available WGS-data will provide a 
genome-wide STR database, which will greatly enhance the 
utility of ExpansionHunter.
Future direction and potential treatments
Advancements in the understanding of pathophysiologic 
mechanisms facilitate the potential to find new therapeu-
tic targets. Current treatment pipelines involve the use of 
pharmacological molecules to target affected downstream 
pathways, as well as genetic therapies to decrease toxic 
polyQ gene products. The former could benefit a larger pro-
portion of patients if the targeted pathway is implicated in 
several neurodegenerative diseases, however, if a mutant 
protein affects multiple cellular processes it could prove 
difficult to target a vital pathway to provide effective treat-
ment [81].
Antisense oligonucleotides
Antisense oligonucleotides (ASOs) are small single-stranded 
sequences of DNA that have the gene-targeting effect of 
reducing levels of toxic protein or making non-toxic modi-
fications which are valuable tools for neurodegenerative 
diseases [82]. Successful uptake of ASOs facilitates their 
gene-modulating effects and relies on effective delivery. 
Mechanisms include lysosomal or endosomal compartmen-
tal internalisation, association with high- and low-binding 
plasma proteins and cellular trafficking.
ASOs decrease the expression of the target protein 
using Watson–Crick hybridization to bind to complemen-
tary mRNA transcripts and recruit RNase H enzymes [83]. 
ASO-mediated exon skipping has been successfully applied 
to SCA3 fibroblasts, removing the central 88 amino acid 
region of the ataxin-3 protein in one study to halt production 
of potentially toxic cleavage fragments; however, protein-
modification effect was at a low-level [84, 85]. ASO therapy 
targeting SCA3 mice models has also been shown to reduce 
disease protein levels by greater than 50% in the cerebellum, 
diencephalon, cervical spinal cord and forebrain, presenting 
with no signs of microgliosis and astrogliosis, indicating its 
potential for a well-tolerated preventative therapy despite 
no observable reduction in motor phenotype [86, 87]. ASO 
therapy targeting ATXN2 has shown slowed progression of 
the motor phenotype and improved survival in both SCA2 
[81] and ALS transgenic mouse model TDP-43 [88].
RNA based therapy
Therapeutics based on RNA interface (RNAi) harness the 
cellular mechanism of gene expression silencing to reduce 
the expression of pathological proteins. Synthetic small 
interfering RNA (siRNAs) and short hairpin RNA (shRNAs) 
control the RNAi process of target mRNA enzymatic cleav-
age in a predictable and consistent action [89]. RNAi has 
been successfully used to reduce mutant ataxin-7 in SCA7 
mouse models in a nonallele- [90] and allele-specific manner 
[91]. ATXN3 has also been suppressed in Machado–Joseph 
disease (MJD) mouse models, with reports of improved 
motor symptoms and neuropathology [92, 93].
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Stem cell based therapy
Some stem cell-based therapies have been performed 
on several cerebellar mutant mice, such as SCA1 mouse 
models [94–98], with reports of normalized motor deficits 
and reduced Purkinje cell loss and SCA2 models which 
showed delayed onset of motor function deterioration 
[99]. Phase I and II clinical trials, one of which involved 
intravenously infused human umbilical cord mesenchymal 
stem cell (UC-MSC) into SCA1, 2 or 3 cohorts (n = 16) 
reported no transplantation side effects and an improved 
International Cooperative Ataxia Rating Scale (ICARS) 
and Berg Balance Scale (BBS) score after 6 months post-
transplantation [100]. Another trial on 14 SCA patients 
using intrathecal injection of UC-MSC reported significant 
ICARS and Activity of Daily Living Scale (ADL) scores, 
which decreased after 1 month of treatment, although 8 
patients remained stable for 6–9 months post-transplanta-
tion [101]. These suggest a potential proof of principle for 
stem cell therapy as a therapeutic intervention, however, 
assessment of efficacy and safety requires further clinical 
trials.
Conclusions
Tremendous scientific progress has occurred in the under-
standing of spinocerebellar ataxia. Next-generation sequenc-
ing has helped improve the diagnostic accuracy of SCAs and 
discover new disease mechanisms. New technologies such as 
nanopore and ExpansionHunter may help improve diagnosis 
of known and new SCAs with repeat expansions in future. 
As outlined, evidence suggests that genes in DNA repair 
pathways appear to play a modifying role. An international 
GWAS of repeat expansion ataxia would be worthwhile 
to pursue these potential therapeutic targets. Meanwhile, 
emerging therapies for neurogenetic diseases such as ASOs 
also provide physicians and patients of SCA hopes of effec-
tive treatments in the near future.
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